The network is generic and will be made specific to different cell types (CD4+ or CD8+), cell conditions (treated or non-treated), and localization (in the lymph node or in the tumour microenvironment) based on specific sets of initial conditions (Table 1). This evidence concerns the gene CD8A and neoplasm.